Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC

By sjmartinez • April 18, 2023

Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. Cancer Discov. 2023 Apr 17:CD-22-1420. doi: 10.1158/2159-8290.CD-22-1420. Epub ahead of print. PMID: 37068173.

Tags: Hematology/Oncology, Publications

Characteristics of clinical trials associated with appeal and return on investment to participants, A Review and Framework

Fernandez Turizo MJ, Velez MA, Glenn B, Cummings AL, Segarra-Vazquez B, Gorbatov S, Park SJ, Shen C, Lind-Lebuffe JP, Unger JM, Garon EB. Characteristics of[...]

IGF2BP3 redirects glycolytic flux to promote one-carbon metabolism and RNA methylation

Sharma G, Gutierrez M, Jones AE, Kapoor S, Jaiswal AK, Neeb ZT, Rios A, Dorairaj P, Thaxton ML, Lin TL, Tran TM, Kabbani LES, Ritter[...]

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial

Fasching PA, Stroyakovskiy D, Yardley DA, Huang CS, Crown J, Bardia A, Chia S, Im SA, Martin M, Xu B, Loi S, Barrios C, Untch[...]